ASX:CSLBiotechs
CSL (ASX:CSL) Shares Confront Profit Reversal As Recovery Case Stays Unproven
CSL stock went into this result having climbed over the past quarter, closing at A$157.82, yet the latest numbers land with a jolt. The global biotech giant posted a trailing twelve month loss from continuing operations of US$2.99b on revenue of US$15.80b. That kind of earnings squeeze grabs short term traders by the throat. For long term investors, the real question now is how to weigh that loss against analyst forecasts that point to a return to profitability, as well as the current gap...